329 related articles for article (PubMed ID: 23907509)
1. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy.
Zhang Y; Nester CM; Holanda DG; Marsh HC; Hammond RA; Thomas LJ; Meyer NC; Hunsicker LG; Sethi S; Smith RJ
J Am Soc Nephrol; 2013 Nov; 24(11):1820-9. PubMed ID: 23907509
[TBL] [Abstract][Full Text] [Related]
2. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
3. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
4. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
6. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
7. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
8. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
9. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.
Chauvet S; Roumenina LT; Bruneau S; Marinozzi MC; Rybkine T; Schramm EC; Java A; Atkinson JP; Aldigier JC; Bridoux F; Touchard G; Fremeaux-Bacchi V
J Am Soc Nephrol; 2016 Jun; 27(6):1665-77. PubMed ID: 26471127
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
11. C3 glomerulopathy: clinicopathologic features and predictors of outcome.
Medjeral-Thomas NR; O'Shaughnessy MM; O'Regan JA; Traynor C; Flanagan M; Wong L; Teoh CW; Awan A; Waldron M; Cairns T; O'Kelly P; Dorman AM; Pickering MC; Conlon PJ; Cook HT
Clin J Am Soc Nephrol; 2014 Jan; 9(1):46-53. PubMed ID: 24178974
[TBL] [Abstract][Full Text] [Related]
12. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
13. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
14. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY.
Trutin I; Oletić L; Galešić Ljubanović D; Turudić D; Milošević D
Acta Clin Croat; 2021 Mar; 60(1):141-145. PubMed ID: 34588735
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
Madden B; Singh RD; Haas M; Palma LMP; Sharma A; Vargas MJ; Gross L; Negron V; Nate T; Charlesworth MC; Theis JD; Nasr SH; Nath KA; Fervenza FC; Sethi S
Kidney Int; 2024 May; 105(5):1077-1087. PubMed ID: 38447879
[TBL] [Abstract][Full Text] [Related]
16. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
17. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
Xiao X; Pickering MC; Smith RJ
Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
[TBL] [Abstract][Full Text] [Related]
18. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
20. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]